Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Norditek in conjunction with its listing on Nasdaq First North
Mandate

Vinge advises Norditek in conjunction with its listing on Nasdaq First North

November 10, 2021 Capital Markets and Public M&A

Vinge has advised Norditek Group AB in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 10 November 2021. In connection with the listing, an invitation to subscribe for shares for a subscription price of SEK 11 was implemented, which was significantly oversubscribed by approximately 4.5 times.

Norditek Group is an environment technology company which focuses on mobile and flexible recycling stations in the fields of Waste, Sand & Rock and Biomass. The company both develops and sells stations by a tried and tested offering which facilitates cost reductions for its customers at the same time as the customers contribute to a more circular society.

Vinge’s team primarily consisted of Anders Strid, Jenny Sandlund (project manager), Beatrice Randow and Anna Högsten.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025